CBD reversed dopamine overactivity and memory deficits in a rat model of schizophrenia
Acute CBD treatment reversed the heightened dopamine neuron activity seen in both male and female MAM rats and improved memory deficits in males, supporting CBD's potential antipsychotic-like effects.
Quick Facts
What This Study Found
Both male and female MAM rats showed increased VTA dopamine neuron population activity, which was reversed by CBD (60 mg/kg) in both sexes. CBD also reversed memory impairment in male MAM rats, while females showed no memory deficits to reverse.
Key Numbers
CBD: 60 mg/kg. Both sexes showed increased VTA DA activity (reversed by CBD). Male MAM rats had NOR deficits (reversed by CBD). Female MAM rats had no NOR deficits. Anxiety in EPM not reversed by CBD.
How They Did This
MAM model: pregnant rats received MAM or saline on GD17. Adult offspring tested on EPM, NOR, MK-801 locomotor response. In vivo electrophysiology of VTA DA neurons. CBD (60 mg/kg) given 1 hour before each test.
Why This Research Matters
Current antipsychotics primarily block dopamine D2 receptors with significant side effects. CBD's ability to normalize dopamine system activity through a different mechanism supports it as a potential alternative.
The Bigger Picture
Finding that CBD normalizes the upstream dopamine system activity that drives psychotic symptoms offers a fundamentally different therapeutic approach from current D2 blockers.
What This Study Doesn't Tell Us
MAM model captures some but not all schizophrenia features. Acute treatment only. Sex differences complicate interpretation. Animal behavior does not directly translate to human psychosis.
Questions This Raises
- ?Would chronic CBD treatment maintain these effects?
- ?Why do female MAM rats not show memory deficits?
Trust & Context
- Key Stat:
- CBD normalized VTA dopamine neuron overactivity in both sexes
- Evidence Grade:
- Rigorous electrophysiology combined with behavioral testing in a validated model, limited by acute dosing and animal-to-human translation.
- Study Age:
- Published in 2025.
- Original Title:
- Cannabidiol attenuates behavioral and electrophysiological changes in the MAM model of schizophrenia in male and female rats.
- Published In:
- Schizophrenia research, 286, 63-73 (2025)
- Authors:
- Fabris, Débora, Andrade, Lídia M, Freitas, Ícaro Silva, Gomes, Felipe V, Guimarães, Francisco S
- Database ID:
- RTHC-06429
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Could CBD treat schizophrenia?
This animal study found CBD reversed dopamine overactivity that drives psychotic symptoms. Human trials are ongoing but mixed.
Does CBD work differently in males and females?
CBD reversed memory deficits only in males (females had no deficits), but normalized dopamine activity in both sexes.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-06429APA
Fabris, Débora; Andrade, Lídia M; Freitas, Ícaro Silva; Gomes, Felipe V; Guimarães, Francisco S. (2025). Cannabidiol attenuates behavioral and electrophysiological changes in the MAM model of schizophrenia in male and female rats.. Schizophrenia research, 286, 63-73. https://doi.org/10.1016/j.schres.2025.10.012
MLA
Fabris, Débora, et al. "Cannabidiol attenuates behavioral and electrophysiological changes in the MAM model of schizophrenia in male and female rats.." Schizophrenia research, 2025. https://doi.org/10.1016/j.schres.2025.10.012
RethinkTHC
RethinkTHC Research Database. "Cannabidiol attenuates behavioral and electrophysiological c..." RTHC-06429. Retrieved from https://rethinkthc.com/research/fabris-2025-cannabidiol-attenuates-behavioral-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.